Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Industrials · ·
$76.60
▼ $0.37 (-0.5%)
Market data updated: 09/20 05:59 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/20/2026
Market Cap
Not available
Day Range
$75.21 - $78.08
52-Week Range
$11.16 - $79.94
Beta
—
Next Earnings
04.11.2026
Support
$41.44
Resistance
$79.94
TXG is a stock from the Industrials sector — Manufacturing, aerospace, defense, and infrastructure — closely tied to capital-investment cycles and economic growth.
+477.2% (1Y)
Strengths: 17/29 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 77.0%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $18.59 vs. price $76.60 (-75.7%)
Fair Value
Signal tension
Growth scores strong (76/100), but fair-value analysis scores this stock as relatively expensive (38/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
60
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
76
Quality
58
Value
38
Momentum
85
Risk
40
Sentiment
68
Fundamental
35
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **10x Genomics, Inc.** has centered on its strong stock performance, surging **84% in three months**, driven by robust demand for its consumables and Atera products, alongside upward revenue guidance. Analysts, including RBC Capital, have initiated coverage with a **Sector Perform rating and a $70 price target**, emphasizing the need for **meaningful growth in its single-cell business** to sustain momentum. The company’s position in **spatial omics** and broader genomics trends has also been highlighted as a key growth driver.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about 10x Genomics, Inc.. News trend score: 68. Reason: 7 of the last 20 articles are positive, versus 4 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
72
🎯 Conviction (vs. Emotion)
42
Investors appear highly excited (72), but evidence of strong fundamental conviction is comparatively weak (42).
Psychology
82
Fundamentals
35
Technical
85
Valuation
38
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price (3M)
+120%
Market Narrative
87
Fundamental Reality
42
Narrative Gap
+45
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
TXG’s psychology score (63) reflects a dominant euphoric state, where extreme valuation (+253% vs. DCF) and perfect sentiment (100/100) drive speculative enthusiasm. FOMO and overconfidence reinforce momentum-driven buying, while anchoring near resistance hints at traders fixating on short-term targets. The 38-point narrative gap (80 vs. 42) suggests reality lags perception, fueling detached optimism. Key question: Will traders sustain euphoria despite extreme valuation, or will anchoring near resistance trigger profit-taking?
Updated: 09/09/2026, 09:28 AM
What could change this?
👥 What the crowd believes
"10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position"
"10x Genomics needs 'meaningful' growth in Single-Cell Business"
"TXG's 84% rally is backed by... but weak instruments and valuation raise the bar"
"RBC Capital initiates coverage on 10x Genomics with Sector Perform rating"
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for TXG reflects deep methodological contrasts: Walter Bagehot’s near-perfect score highlights its liquidity resilience in a credit crisis, aligning with his focus on financial stability, while Peter Lynch’s enthusiasm for growth potential contrasts sharply with the caution of Howard Marks and Samuel Nelson, who see it as late-cycle or overbought. Fisher’s lukewarm approval and Livermore’s indecision suggest a lack of clear momentum or exceptional quality, whereas Graham’s dual verdicts (one defensive, one enterprising) underscore the stock’s valuation ambiguity—cheap enough for some but not for his strict criteria. Meanwhile, the efficient-market camp dismisses it as unconvincing, while Mackay’s warning about crowd behavior and Loeb’s risk flag point to speculative or speculative-leaning traits that clash with their conservative frameworks.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 86
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 72
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 54
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 54
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 39
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 35
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 33
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 25
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 23
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 16
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 0
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 2 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
69.1%
Operating Margin
-9.5%
Net Margin
-6.8%
EBITDA Margin
-3.9%
ROE
-5.5%
ROA
-4.2%
ROIC
—
EPS
-$0.35
Cash
$473.97M
Total Debt
—
Current Ratio
4.46
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$76.60
Estimated Fair Value (DCF)
$18.59
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-75.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
7.9%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 7.9% | $140.43M | $128.83M |
| 2 | 6.6% | $149.65M | $125.96M |
| 3 | 5.2% | $157.45M | $121.58M |
| 4 | 3.9% | $163.52M | $115.84M |
| 5 | 2.5% | $167.61M | $108.94M |
Base FCF (last actual year)
$130.12M
Terminal Value
$2.64B
Present Value of Terminal Value
$1.72B
Enterprise Value
$2.32B
Net Debt
$0
Equity Value
$2.32B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$6.38
Tangible Book Value per Share (Tangible NAV)
$5.85
Sentiment based on basic keywords (not AI) — 7 positive, 9 neutral, 4 negative out of the last 20 articles.
Yahoo · 19.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 15.9.2026
Benzinga · 15.9.2026
StockStory · 12.9.2026
Yahoo · 12.9.2026
MT Newswires · 11.9.2026
MT Newswires · 10.9.2026
PR Newswire · 10.9.2026
Yahoo · 10.9.2026
GlobeNewswire · 10.9.2026
Benzinga · 10.9.2026
Yahoo · 9.9.2026
Benzinga · 9.9.2026
MT Newswires · 9.9.2026
MT Newswires · 9.9.2026
Yahoo · 8.9.2026
GlobeNewswire · 8.9.2026
StockStory · 4.9.2026
10x Genomics, Inc. (TXG) currently has a StockIQ AI score of 60/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
TXG currently scores 60/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, TXG's estimated fair value is $18.59, which is 75.7% below the current price of $76.60. This is one valuation model among several signals in the fair-value category, not a price target.
TXG's technical score is 85/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 77.0%; Free cash flow growth: 2371.2%; Net income growth: 76.2%.
Based on the real signals StockIQ computed: Estimated fair value: $18.59 vs. price $76.60 (-75.7%); Operating margin: -9.5% (negative); Net margin: -6.8% (negative).
StockIQ has no recorded dividend payment history for TXG.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 22 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Taich Adam | Open Market Sale | 9.9.2026 | 13,754 | -13,754 | $65.26 |
| Taich Adam | Open Market Sale | 9.9.2026 | 31,428 | -31,428 | $64.31 |
| Taich Adam | Open Market Sale | 9.9.2026 | 1,206 | -1,206 | $63.68 |
| STUELPNAGEL JOHN R | Open Market Sale | 3.9.2026 | 6,814 | -6,814 | $62.11 |
| STUELPNAGEL JOHN R | Open Market Sale | 3.9.2026 | 7,012 | -7,012 | $60.66 |
| STUELPNAGEL JOHN R | Open Market Sale | 3.9.2026 | 6,174 | -6,174 | $62.61 |
| Saxonov Serge | Gift | 1.9.2026 | 100 | -100 | — |
| Saxonov Serge | Open Market Sale | 26.8.2026 | 1,082,335 | -3,500 | $63.02 |
| Saxonov Serge | Open Market Sale | 26.8.2026 | 1,075,841 | -6,494 | $63.98 |
| Saxonov Serge | Open Market Sale | 26.8.2026 | 1,075,349 | -492 | $64.75 |
| Saxonov Serge | Open Market Sale | 26.8.2026 | 6,494 | -6,494 | $63.98 |
| Saxonov Serge | Open Market Sale | 26.8.2026 | 3,500 | -3,500 | $63.02 |
| Saxonov Serge | Open Market Sale | 26.8.2026 | 492 | -492 | $64.75 |
| Hindson Benjamin J. | Open Market Sale | 24.8.2026 | 13,818 | -13,818 | $63.02 |
| SULIMAN SHEHNAAZ | Open Market Sale | 24.8.2026 | 561 | -561 | $62.73 |
| Saxonov Serge | Open Market Sale | 24.8.2026 | 18,545 | -18,545 | $63.02 |
| Taich Adam | Open Market Sale | 24.8.2026 | 17,166 | -17,166 | $63.02 |
| SULIMAN SHEHNAAZ | Open Market Sale | 24.8.2026 | 1,646 | -1,646 | $63.97 |
| SULIMAN SHEHNAAZ | Open Market Sale | 24.8.2026 | 29,515 | -1,646 | $63.97 |
| Saxonov Serge | Open Market Sale | 24.8.2026 | 1,085,835 | -18,545 | $63.02 |
| SULIMAN SHEHNAAZ | Open Market Sale | 24.8.2026 | 31,161 | -561 | $62.73 |
| Taich Adam | Open Market Sale | 24.8.2026 | 362,732 | -17,166 | $63.02 |
| Hindson Benjamin J. | Open Market Sale | 24.8.2026 | 488,182 | -13,818 | $63.02 |
| Saxonov Serge | Gift | 20.8.2026 | 1,104,380 | -4,000 | — |
| Saxonov Serge | Gift | 20.8.2026 | 4,000 | -4,000 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
16,161,855 shares short as of 2026-08-31 · vs. 15,625,594 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
52.9% of trading volume this week was short selling, vs. 72.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology